Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endoplasmic reticulum lumen |
Domain |
PF01532 Glycosyl hydrolase family 47 PF02225 PA domain |
Function |
Involved in endoplasmic reticulum-associated degradation (ERAD). Accelerates the glycoprotein ERAD by proteasomes, by catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2 in the N-glycans. Seems to have alpha 1,2-mannosidase activity (By similarity). |
Biological Process |
GO:0006486 protein glycosylation GO:0006487 protein N-linked glycosylation GO:0006491 N-glycan processing GO:0006516 glycoprotein catabolic process GO:0006517 protein deglycosylation GO:0006986 response to unfolded protein GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0009311 oligosaccharide metabolic process GO:0010498 proteasomal protein catabolic process GO:0030433 ER-associated ubiquitin-dependent protein catabolic process GO:0030968 endoplasmic reticulum unfolded protein response GO:0034620 cellular response to unfolded protein GO:0034976 response to endoplasmic reticulum stress GO:0035966 response to topologically incorrect protein GO:0035967 cellular response to topologically incorrect protein GO:0035977 protein deglycosylation involved in glycoprotein catabolic process GO:0036503 ERAD pathway GO:0036507 protein demannosylation GO:0036508 protein alpha-1,2-demannosylation GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043413 macromolecule glycosylation GO:0044723 single-organism carbohydrate metabolic process GO:0070085 glycosylation GO:0097466 glycoprotein ERAD pathway GO:1901136 carbohydrate derivative catabolic process GO:1904380 endoplasmic reticulum mannose trimming GO:1904382 mannose trimming involved in glycoprotein ERAD pathway GO:1904587 response to glycoprotein |
Molecular Function |
GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds GO:0004559 alpha-mannosidase activity GO:0004569 glycoprotein endo-alpha-1,2-mannosidase activity GO:0004571 mannosyl-oligosaccharide 1,2-alpha-mannosidase activity GO:0015923 mannosidase activity GO:0015924 mannosyl-oligosaccharide mannosidase activity GO:0016798 hydrolase activity, acting on glycosyl bonds |
Cellular Component |
GO:0005788 endoplasmic reticulum lumen GO:0044322 endoplasmic reticulum quality control compartment |
KEGG |
hsa04141 Protein processing in endoplasmic reticulum |
Reactome |
R-HSA-446203: Asparagine N-linked glycosylation R-HSA-901042: Calnexin/calreticulin cycle R-HSA-901032: ER Quality Control Compartment (ERQC) R-HSA-392499: Metabolism of proteins R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle R-HSA-597592: Post-translational protein modification |
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between EDEM3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of EDEM3 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of EDEM3 in various data sets.
|
Points in the above scatter plot represent the mutation difference of EDEM3 in various data sets.
|
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EDEM3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EDEM3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EDEM3. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EDEM3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of EDEM3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between EDEM3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | EDEM3 |
Name | ER degradation enhancer, mannosidase alpha-like 3 |
Aliases | C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ...... |
Chromosomal Location | 1q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting EDEM3 collected from DrugBank database. |
There is no record. |